Joseph J. Eron, Jr., MD, describes new data on the investigational maturation inhibitor bevirimat and entry inhibitor PRO 140 and discusses the reanalysis of data from the MERIT trial.

Joel E. Gallant, MD, MPH, reports on the phase III STARTMRK trial of raltegravir vs efavirenz in antiretroviral-naive patients and on the NA-ACCORD cohort study on when to start antiretroviral therapy.

Anton L. Pozniak, MD, FRCP, reports on the 96-week results from the CASTLE, ARTEMIS, and HEAT clinical trials in treatment-naive patients as well as several analyses on the use of abacavir in patients with high HIV-1 RNA.

Sharon L. Walmsley, MSc, MD, FRCPC, reports on several analyses from clinical trials that inform on the assessment of activity of antiretroviral agents in treatment-experienced patients and the optimal construction of regimens for these patients.

Daniel R. Kuritzkes, MD, discusses new data on raltegravir mechanism of action, resistance to integrase inhibitors, viral tropism, and prevalence of the K65R mutation in populations with subtype C virus.

Mauro Schechter, MD, PhD, discusses the controversial question of when to start antiretroviral therapy in TB and HIV coinfected patients.

Andrew Carr, MBBS, MD, FRACP, FRCP, discusses recent data regarding markers of inflammation and other processes that are associated with atherosclerosis and cardiovascular disease in HIV-infected patients.

Andrew R. Zolopa, MD, and Kimberly Y. Smith, MD, MPH, offer their perspectives on the potential clinical implications of the new data on abacavir and cardiovascular risk presented at the 2008 International AIDS Conference in Mexico City.

Joseph J. Eron, Jr., MD, summarizes key presentations from the 2008 International AIDS Conference that are likely to impact the management of treatment-experienced patients.

Anton L. Pozniak, MD, FRCP, who is a panel member for the European AIDS Clinical Society and British HIV Association guidelines, provides insight on when to start antiretroviral therapy and explains why differences may exist between guidelines on which...

Mauro Schechter, MD, PhD, highlights what he expects to be some of the most important presentations at this years International AIDS Conference.

Jose Gatell, MD, provides an overview of presentations on the new IAS treatment guidelines, HAART-associated complications, and tuberculosis coinfection, and then speculates on the future of an HIV vaccine.

Jurgen K. Rockstroh, MD, discusses the results of key reports on HIV comorbidities from the 2008 International AIDS Conference, including the incidence and treatment of tuberculosis as well as hepatitis in HIV-coinfected patients.

Sharon L. Walmsley, MSc, MD, FRCPC, gives an overview of the top issues and studies that will be presented at this years International AIDS Conference.

Kimberly Y. Smith, MD, MPH, discusses the efficacy and safety data from 3 studies presented at the 2008 International AIDS Conference, each investigating newer antiretroviral agents compared with efavirenz in treatment-naive patients.

Joel E. Gallant, MD, reclinically relevant data from presentations on first-line antiretroviral therapy from the 2008 International AIDS Conference.

Kathleen E. Squires, MD, recaps studies that will likely impact the management of HIV-infected women while she was on location at the 2008 International AIDS Conference.

Anton L. Pozniak, MD, FRCP, redata from studies investigating antiretroviral resistance in resource-limited countries.

Anton L. Pozniak, MD, FRCP, redata from studies investigating antiretroviral resistance in resource-limited countries.